ERBB2 and breast cancer: In the few cases where robust biomarkers have been identified, such as HER2 amplification for trastuzumab treatment of breast cancer and lack of K-ras mutations for erlotinib treatment of non-small cell lung cancer (3,4), patient subsets that benefit significantly can be readily distinguished.